Cryoport Systems Featured in Contract Pharma: The Power of an Integrated Supply Chain
We’re excited to share that Contract Pharma recently featured Cryoport Systems in a new Q&A article spotlighting our integrated, end-to-end supply chain platform for cell and gene therapies. The piece highlights insights from Matthew Frazzetta, Vice President of Global Accounts, BioServices at Cryoport Systems, and explores how we are supporting the growing needs of life sciences companies around the world.
In the interview, Matthew discusses how Cryoport Systems delivers a truly integrated platform that brings together cryopreservation, biostorage, packaging, labeling, regulatory support, and direct-to-site distribution, all within a unified global infrastructure. This comprehensive approach ensures consistency, scalability, and quality across every stage of the therapy lifecycle, setting us apart from fragmented service models.
Key themes from the article include:
- The power of an integrated, end-to-end model that centralizes services under one global platform to reduce handoffs and minimize risk
- Supporting both CDMOs and therapeutic sponsors with tailored, program-specific supply chain management
- Implementing risk mitigation strategies and 24/7 monitoring to maintain product integrity and minimize disruptions
- Scaling to meet the future as advanced therapies expand beyond oncology into broader therapeutic areas
Whether it’s early-stage development or commercial launch, Cryoport Systems is building today to support tomorrow’s breakthroughs.
Read the full interview on Contract Pharma: The Power of an Integrated Cell & Gene Therapy Supply Chain